Table 2 Frequencies of hepatitis C virus (HCV) specific BrdU+ T cells in subjects with acute self limiting infection and those with chronic evolution.
| Subject No | Infecting genotype | Infection outcome | Peptide pool | Time: 0–1 months | Time: 6 months | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ELISpot* | BrdU CD4† | CD8‡ | ELISpot* | BrdU CD4† | CD8‡ | ||||||
| A24 | 1b | Self limited | NS3h | 275 | + | 0.09 | 0.05 | 48 | − | 0.00 | 0.00 |
| NS3p | 168 | + | 0.19 | 0.05 | 33 | − | 0.02 | 0.01 | |||
| A45 | 1b | Self limited | NS3h | 123 | − | 0.01 | 0.00 | 558 | + | 0.01 | 0.04 |
| A50 | 1b | Self limited | NS3h | 876 | + | 0.17 | 0.20 | 128 | + | 0.12 | 0.02 |
| A25 | 1b | Self limited | NS3h | 370 | nd | nd | Nd | 30 | + | 0.01 | 0.04 |
| A46 | 1b | Self limited | NS3h | 395 | nd | nd | Nd | 315 | + | 0.04 | 0.14 |
| NS5bI | 300 | nd | nd | Nd | 168 | + | 0.03 | 0.05 | |||
| A43 | 3a | Self limited | NS4 | 193 | + | 0.46 | 0.03 | 48 | + | 0.04 | 0.16 |
| A35 | 1b | Chronic | NS3p | 217 | + | 0.00 | 0.07 | 85 | − | 0.01 | 0.00 |
| NS4 | 313 | − | 0.00 | 0.03 | 88 | − | 0.01 | 0.03 | |||
| A49 | 1a | Chronic | NS3h | 363 | − | 0.03 | 0.03 | 150 | − | 0.03 | 0.01 |
| A34 | 1b | Chronic | NS3h | 133 | − | 0.00 | 0.00 | 58 | − | 0.00 | 0.00 |
| A27 | 1a | Chronic | NS3h | 60 | − | 0.01 | 0.01 | 110 | − | 0.00 | 0.03 |
| A1 | 3a | Chronic | NS3h | 278 | + | 0.04 | 0.38 | 95 | − | 0.01 | 0.01 |
| NS3p | 168 | − | 0.01 | 0.01 | 53 | − | 0.01 | 0.01 | |||
| A18 | 3a | Chronic | Core | 173 | − | 0.00 | 0.01 | 135 | − | 0.01 | 0.01 |
*Spot forming cells (SFC)/106 peripheral blood mononuclear cells (PBMC) (positive values are in bold type).
†%BrdU+CD4+/total CD4+CD3+ (positive values are in bold type).
‡%BrdU+CD8+/total CD8+CD3+ (positive values are in bold type).
nd, not done.
Several additional data are included: patient ID, infecting genotype, outcome of infection, peptide pool used for ex vivo stimulation of PBMC, and frequencies of BrdU+ T cells measured at 0–1 month and at six months. ELIspot data are included to compare the number of SFC/106 PBMC measured in the patient at the corresponding time point and with the corresponding peptide pool. A positive proliferation response is indicated with a + when the frequency of BrdU+ CD8+ or CD4+ T cells was above the threshold set in the assay validation and three times the background of the unstimulated control (see methods).